Exemestane Completed Phase 2 Trials for Estrogen-receptor Positive Invasive Metastatic Breast Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01594216Ruxolitinib in Estrogen Receptor Positive Breast Cancer